



(11)

**EP 3 735 267 B8**

(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

- (15) Correction information:  
**Corrected version no 1 (W1 B1)**  
**Corrections, see**  
**Bibliography INID code(s) 54**
- (48) Corrigendum issued on:  
**09.11.2022 Bulletin 2022/45**
- (45) Date of publication and mention of the grant of the patent:  
**14.09.2022 Bulletin 2022/37**
- (21) Application number: **19705386.1**
- (22) Date of filing: **04.01.2019**
- (51) International Patent Classification (IPC):  
**A61K 39/00** <sup>(2006.01)</sup> **A61K 31/4745** <sup>(2006.01)</sup>  
**A61K 31/513** <sup>(2006.01)</sup> **A61K 31/519** <sup>(2006.01)</sup>  
**A61K 31/555** <sup>(2006.01)</sup> **A61P 35/00** <sup>(2006.01)</sup>
- (52) Cooperative Patent Classification (CPC):  
(C-Sets available)  
**A61K 31/4745; A61K 31/513; A61K 31/519;**  
**A61P 35/00; C07K 16/00; C07K 16/22;**  
A61K 2039/505; C07K 2317/24; C07K 2317/73;  
C07K 2317/76 (Cont.)
- (86) International application number:  
**PCT/IB2019/000008**
- (87) International publication number:  
**WO 2019/135157 (11.07.2019 Gazette 2019/28)**

(54) **ADMINISTRATION OF MULTIPLE BOLUSES OF [6R] MTHF IN A 5-FLUOROURACIL-BASED CHEMOTHERAPY**

[6R]-MTHF-BOLUS-MEHRFACHVERABREICHUNG IN 5-FLUORURACIL-BASIERTER CHEMOTHERAPIE

ADMINISTRATION DE BOLUS MULTIPLES [6R]-MTHF DANS UNE CHIMIOTHÉRAPIE À BASE DE 5-FLUOROURACILE

- (84) Designated Contracting States:  
**AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR**
- (30) Priority: **05.01.2018 PCT/EP2018/050274**  
**03.04.2018 US 201862651910 P**  
**19.11.2018 US 201862769289 P**
- (43) Date of publication of application:  
**11.11.2020 Bulletin 2020/46**
- (73) Proprietor: **Isofol Medical AB**  
**413 46 Göteborg (SE)**
- (72) Inventors:  
• **Ganlöv, Karin**  
**411 25 Göteborg (SE)**  
• **Östberg, Magnus**  
**416 53 Göteborg (SE)**  
• **Lindberg, Per L.**  
**413 01 Göteborg (SE)**
- **Sundén, Gunnel E.**  
**41301 Gothenburg (SE)**  
• **Gustavsson, Bengt**  
**426 79 Vastra Frolunda (SE)**
- (74) Representative: **AWA Denmark A/S**  
**Strandgade 56**  
**1401 Copenhagen K (DK)**
- (56) References cited:  
**WO-A2-2005/097086 WO-A2-2007/064968**

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

**EP 3 735 267 B8**

- **Muhammad Wasif Saif ET AL: "Phase III Multicenter Randomized Clinical Trial to Evaluate the Safety and Efficacy of CoFactor / 5-Fluorouracil/Bevacizumab Versus Leucovorin/ 5-Fluorouracil/Bevacizumab as Initial Treatment for Metastatic Colorectal Carcinoma", Clinical Colorectal Cancer, 1 September 2006 (2006-09-01), pages 229-234, XP055358951, Retrieved from the Internet: URL:[http://www.clinical-colorectal-cancer.com/article/S1533-0028\(11\)70289-4/pdf](http://www.clinical-colorectal-cancer.com/article/S1533-0028(11)70289-4/pdf) [retrieved on 2017-03-27]**

(52) Cooperative Patent Classification (CPC): (Cont.)

C-Sets

**A61K 31/4745, A61K 2300/00;**

**A61K 31/513, A61K 2300/00;**

**A61K 31/519, A61K 2300/00**